Sanofi (SNY) Net Income towards Common Stockholders (2009 - 2026)

Sanofi has disclosed Net Income towards Common Stockholders across 18 years of filings, most recently posting $30.4 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at $30.4 million, down 83.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.1 billion (up 3539.21% YoY), and the FY2025 annual result was $9.1 billion, up 53.07% from the prior year.
• Net Income towards Common Stockholders came in at $30.4 million for Q1 2026 at Sanofi, up from -$3.3 billion in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $6.7 billion in Q4 2022 to a low of -$3.3 billion in Q4 2025.
• The 5-year median for Net Income towards Common Stockholders is $1.8 billion (2022), against an average of $1.7 billion.
• Peak annual rise in Net Income towards Common Stockholders reached 7513.84% in 2025, while the deepest fall reached 1655.15% in 2025.
• Sanofi's Net Income towards Common Stockholders stood at $6.7 billion in 2022, then sank by 107.07% to -$472.3 million in 2023, then soared by 59.73% to -$190.2 million in 2024, then plunged by 1655.15% to -$3.3 billion in 2025, then jumped by 100.91% to $30.4 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $30.4 million (Q1 2026), -$3.3 billion (Q4 2025), and $3.3 billion (Q3 2025), per Business Quant data.